Evidence Level
Moderate
3 Clinical Trials
5 Documented Benefits
3/5 Evidence Score

Ergothioneine (EGT) is a naturally occurring amino acid and potent antioxidant synthesized exclusively by certain fungi, bacteria, and actinomycetes — humans cannot produce it and must obtain it from diet (primarily mushrooms) or supplementation. Remarkably, the human body has evolved a dedicated transporter (OCTN1) that actively concentrates ergothioneine in tissues under oxidative stress — suggesting it plays an essential protective role. ErgoActive® (Blue California) is a fermentation-derived ergothioneine with mounting evidence for its role as a 'longevity vitamin,' protecting mitochondria, DNA, and cells from damage associated with aging and chronic disease.

Studied Dose 5–30 mg/day; most human studies use 5–20 mg/day; dietary intake from mushrooms typically 1–5 mg/day; therapeutic range being established in ongoing trials
Active Compound L-Ergothioneine (≥98% pure) — ErgoActive® by Blue California (fermentation-derived; also available from Tetrahedron and other suppliers; mushroom-sourced forms also available)

Exceptional cellular antioxidant protection

Ergothioneine is uniquely concentrated by the OCTN1 transporter in cells under oxidative stress — particularly in mitochondria, nuclei, red blood cells, and tissues with high oxidative exposure (liver, kidneys, eyes, brain). Unlike most antioxidants that distribute passively, EGT is actively delivered to the exact cellular locations where protection is most needed.

Mitochondrial protection and bioenergetics

EGT preferentially accumulates in mitochondria and protects the mitochondrial inner membrane from oxidative damage. Clinical studies show EGT supplementation improves mitochondrial function markers, reduces mitochondrial DNA damage, and enhances ATP production efficiency — contributing to the anti-fatigue and energy-supporting effects observed.

Cognitive aging and neurodegeneration prevention

Population studies across multiple countries show plasma ergothioneine levels are significantly lower in patients with mild cognitive impairment and Alzheimer's disease compared to age-matched healthy controls. A Singapore longitudinal study found the lowest quartile of EGT plasma levels had 3x higher risk of developing mild cognitive impairment. Human supplementation trials show cognitive benefits in older adults.

DNA protection and anti-aging

EGT is one of the most potent known protectors of DNA from oxidative damage — specifically shielding guanine residues (the most oxidation-sensitive DNA base) from hydroxyl radical attack. This DNA protective mechanism, combined with telomere length preservation observed in population studies, positions EGT as a foundational anti-aging molecule.

Cardiovascular and metabolic protection

Population studies show an inverse relationship between plasma EGT levels and cardiovascular disease risk, metabolic syndrome, and diabetes. Clinical studies demonstrate EGT reduces oxidized LDL, improves endothelial function, and reduces inflammatory markers (CRP, IL-6) — with mechanisms distinct from and complementary to other antioxidant supplements.

1

OCTN1 transporter-mediated cellular targeting

Ergothioneine is the only known nutrient with a dedicated mammalian transporter (OCTN1/SLC22A4) that actively imports it against concentration gradients into cells experiencing oxidative stress. OCTN1 expression is upregulated in damaged tissue, creating a self-targeting delivery system that concentrates EGT where it is most needed — in mitochondria, cell nuclei, and oxidatively stressed tissues.

2

Thione-thiol redox cycling

EGT exists in equilibrium between its thione (oxidized) and thiol (reduced) forms — unlike most thiols (glutathione, cysteine), EGT's thione form is thermodynamically stable and does not spontaneously oxidize in air. This unique redox chemistry allows EGT to cycle repeatedly between forms without being consumed, providing sustained antioxidant protection at very low concentrations.

3

Metal chelation and Fenton reaction prevention

EGT forms extremely stable complexes with redox-active metal ions (copper, zinc, iron, mercury, cadmium) — preventing them from participating in Fenton reactions that generate the most damaging hydroxyl radicals. This metal chelation is particularly important in the brain and liver where metal accumulation drives neurodegeneration and liver disease respectively.

1
Plasma Ergothioneine and Mild Cognitive Impairment — Singapore Cohort Study
PubMed

Prospective cohort study examining plasma ergothioneine levels in 470 older adults and association with mild cognitive impairment over 2-year follow-up.

470 older adults from Singapore Memory Aging and Cognition Centre cohort.

Plasma ergothioneine levels were significantly lower in subjects who developed mild cognitive impairment. Lowest quartile of EGT had 3x greater MCI risk vs. highest quartile after adjusting for confounders. EGT levels inversely correlated with cognitive decline rate. Establishes EGT as a biomarker and potential protective factor for cognitive aging.

2
Ergothioneine Supplementation and Cognitive Function — Human RCT
PubMed

Randomized, double-blind, placebo-controlled trial of ergothioneine supplementation (20 mg/day) vs. placebo in 40 older adults with subjective cognitive decline for 12 weeks.

40 older adults with subjective cognitive concerns. 12-week intervention.

EGT supplementation significantly improved working memory, attention, and processing speed on computerized cognitive battery vs. placebo. Plasma EGT levels increased 7-fold. Oxidative stress biomarkers reduced. No adverse effects.

3
Ergothioneine and Cardiovascular Risk Biomarkers — Population Study
PubMed

Cross-sectional and longitudinal analysis of plasma ergothioneine levels and cardiovascular disease biomarkers in the PREDIMED study population.

Large cohort study participants with cardiovascular risk factors.

Higher plasma ergothioneine levels significantly associated with lower oxidized LDL, lower CRP, better endothelial function, and reduced 10-year cardiovascular risk scores. EGT levels inversely associated with metabolic syndrome markers. Supports EGT as cardiovascular protective factor.

Common Potential side effects

Excellent safety profile; naturally occurring amino acid present in human tissues throughout life
No adverse effects reported in clinical studies at doses up to 30 mg/day
Extremely low risk profile — the body has evolved a dedicated transporter for this molecule, suggesting evolutionary safety

Important Drug interactions

No established drug interactions at standard supplemental doses (5–30 mg/day)
Immunosuppressants — EGT has immunomodulatory properties; theoretical interaction; consult physician in transplant patients
Heavy metal chelation therapy — EGT chelates metals; potential interaction with pharmaceutical chelation protocols
Generally considered very safe with no known pharmacokinetic interactions